Eli Lilly and Company (LLY)
| Market Cap | 575.32B |
| Revenue (ttm) | 53.26B |
| Net Income (ttm) | 13.80B |
| Shares Out | 897.74M |
| EPS (ttm) | 15.29 |
| PE Ratio | 41.91 |
| Forward PE | 23.69 |
| Dividend | $6.00 (0.94%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 26,101,846 |
| Open | 675.66 |
| Previous Close | 746.37 |
| Day's Range | 633.20 - 678.29 |
| 52-Week Range | 633.20 - 972.53 |
| Beta | 0.44 |
| Analysts | Strong Buy |
| Price Target | 1,015.65 (+58.48%) |
| Earnings Date | Aug 7, 2025 |
About ACCD
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,015.65, which is an increase of 58.48% from the latest price.
News
Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025
We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...
Eli Lilly's Share Price Sheds Some Weight: This Doesn't Mean To Pile In
Eli Lilly delivered strong Q2 results, beating analyst estimates and raising guidance, driven by robust growth in Mounjaro and Zepbound sales. Despite impressive financials, the stock remains expensiv...
S&P 500 Gains and Losses Today: Apple Stock Climbs; Eli Lilly Slumps After Disappointing Trial Results
Major U.S. equities indexes were mixed Thursday after the overnight onset of President Trump's "reciprocal" tariffs, which increased the levies imposed on imports from a broad range of trading partner...
Eli Lilly's oral obesity treatment efficacy falls short of expectations, says BMO's Evan Seigerman
Evan Seigerman, BMO, joins 'Fast Money' to talk the latest oral obesity treatment data out of Eli Lilly.
LLY Plunges on Earnings & Weight Loss Drug Disappointment, Outlook Still Holds Optimism
"This market is priced for perfection," says Rebecca Walser (@walserwealth) and it caused investors to see any red mark on Eli Lilly's (LLY) earnings as bearish. The stock plunged when its oral weight...
Stocks Swing Lower as Eli Lilly, Fortinet Spiral: Stock Market Today
The main indexes finished well off their session highs after a disappointing batch of corporate earnings reports.
Eli Lilly stock sell-off ‘overdone' as weight-loss pill remains ‘commercially viable'
Goldman Sachs analyst Asad Haider says investors are overreacting to the late-stage data Eli Lilly & Co (NYSE: LLY) reported for its experimental oral obesity pill, orforglipron, on Thursday. Lilly re...
Eli Lilly's Experimental Weight-Loss Pill Data Disappoints
A new, late-stage clinical study shows disappointing results for Eli Lilly's weight loss pill Orforglipron. The experimental drug has less success than its injectable counterparts like Zepbound, Wegov...
Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?
It's been a week of wins for Eli Lilly's weight-loss drugs. In the company's second quarter earnings report on Thursday, it reported that sales of Mounjaro, its type-2 diabetes medication often used f...
Leerink's Risinger on Eli Lilly downgrade: Triggered by disappointing obesity pill results
David Risinger, Leerink Partners senior research analyst, joins 'Power Lunch' to discuss how competitive Eli Lilly's business is, what to expect by the end of the decade and much more.
Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here's Why It's Down
Eli Lilly CEO David Ricks told CNBC the company was “not disappointed with these results,” which he noted were “right on thesis for us” despite falling “one or two points below what [Wall Street] had....
Eli Lilly Q2 Earnings: Ignore Oral Weight Loss Bombshell, This Is A Buy The Dip Moment
Eli Lilly delivered strong Q2 results, raising full-year guidance, but shares plunged over 15% due to underwhelming Orforglipron weight loss data. Tirzepatide's explosive growth cements Lilly's domina...
Eli Lilly and Company (LLY) Q2 2025 Earnings Call Transcript
Eli Lilly and Company (NYSE:LLY) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Daniel M. Skovronsky - EVP, Chief Scientific Officer and President of Lilly Research L...
Drugmakers racing to launch the first weight-loss pill
Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo Nordisk's Wegovy.
Top Stock Movers Now: DoorDash, Fortinet, Eli Lilly, and More
U.S. equities were mixed at midday as the market continued to focus on earnings, and new U.S. tariffs kicked in. The Nasdaq was up, while the Dow Jones Industrial Average and S&P 500 fell.
Lilly's New Weight-Loss Pill Underperforms in Study
Eli Lilly & Co.'s new weight-loss pill had lower weight loss and higher rates of nausea and vomiting than anticipated in a study, according to the company. That news sent the stock plunging Thursday m...
Eli Lilly shares drop despite Q2 beat
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest earnings from drugmaker Eli Lilly.
President Trump wants Intel's CEO to resign, Eli Lilly's GLP-1 pill trial disappoints
Morning Brief anchor Julie Hyman breaks down the latest market news for August 7, 2025. President Trump called on Intel CEO Lip-Bu Tan to resign over conflicts of interest concerns, which include ties...
Eli Lilly Weight-Loss Pill Trial Disappoints, Offsetting Solid Profit and Sales
Ely Lilly (LLY) shares sank 14% Thursday when the pharmaceutical firm reported disappointing results from a late-stage study of its experimental obesity pill. The news offset Lilly's strong quarterly ...
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
On Thursday, Eli Lilly and Co.'s LLY weight loss rival Novo Nordisk A/S NVO, along with smaller firms, Terns Pharmaceuticals, Inc. TERN, Viking Therapeutics Inc. VKTX, and Structure Therapeutics Inc. ...
"Disappointment Overall" for LLY Earnings, ABNB Shows Travel Weakness
Eli Lilly's (LLY) earnings beat wasn't enough draw investors in. The bigger focus was on the company's weight loss pill that showed "disappointing" results.
VIEW Lilly's obesity pill lags Novo's Wegovy injection in key trial
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's in...
Eli Lilly CEO David Ricks on Q2 earnings, obesity pill late-stage trial results
CNBC's Angelica Peebles and Eli Lilly chairman and CEO David Ricks join 'Squawk Box' to discuss the company's quarterly earnings results, late-stage trial data on its experimental obesity pill orforgl...
Eli Lilly's obesity pill led to around 12% weight loss in late-stage trial, paving way for approval
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news from Eli Lilly.
Novo Nordisk shares jump as Eli Lilly's weight-loss pill data disappoints
Shares in Novo Nordisk rose 13.6% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell short of expectations, boosting investor confidence in the Danish drugmaker's market-...